Aim: The aim of this study is to assess the effectiveness of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor (HDI) with a broad spectrum epigenetic activity, in improving filtration bleb survival as an adjunct therapy to glaucoma filtration surgery (GFS) in the rabbit model.
Materials and methods: Eighteen New Zealand White rabbits underwent GFS in the left eye and were randomized to receive either a subconjunctival (SC) injection of 0.1 mL SAHA (9.25 μg/mL) or balanced saline solution (BSS) at the end of surgery, or a 3-minute intraoperative topical application of 0.4 mg/mL mitomycin-C (MMC). Bleb survival and histology were compared.
Results: Blebs of rabbits receiving injections of SAHA survived an average (mean ± SD) of 23.2 ± 2.7 days. SAHA rabbits showed a nonsignificant improvement over rabbits that received an injection of BSS, which had a mean survival time of 19.7 ± 2.7 days (p = 0.38) according to a one-way analysis of variance (ANOVA). Eyes receiving intraoperative topical MMC survived an average of 32.5 ± 3.3 days, which is significantly longer than both the control group treated with BSS (p = 0.01) and the experimental group treated with the SAHA (p = 0.0495). SAHA was well tolerated and showed no significant avascularity, necrosis, or conjunctival thinning.
Conclusion: Although it was well tolerated, a single intraoperative injection of SAHA did not significantly prolong bleb survival in the rabbit model.
Clinical significance: Epigenetic adjuncts hold promise for improving GFS outcome; however, future studies must continue to examine different administration protocols and dosages to substantiate their efficacy.
Burr J, Azuara-Blanco A, et al. Medical vs surgical interventions for open angle glaucoma. Cochrane Database Syst Rev 2012;(9):CD004399. DOI: 10.1002/14651858.CD004399.pub3.
DeBry PW, Perkins TW, et al. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol 2002;120(3):297–300. DOI: 10.1001/archopht.120.3.297.
Francis BA, Du LT, et al. Histopathologic features of conjunctival filtering blebs. Arch Ophthalmol 2005;123(2):166–170. DOI: 10.1001/archopht.123.2.166.
Muckley ED, Lehrer RA. Late-onset blebitis/endophthalmitis: incidence and outcomes with mitomycin C. Optom Vis Sci 2004;81(7):499–504. DOI: 10.1097/00006324-200407000-00010.
Martorana GM, Schaefer JL, et al. Sequential Therapy with Saratin, Bevacizumab and Ilomastat to Prolong Bleb Function following Glaucoma Filtration Surgery in a Rabbit Model. PLoS One 2015;10(9):e0138054. DOI: 10.1371/journal.pone.0138054.
Anand N, Arora S, et al. Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks. Br J Ophthalmol 2006;90(2):175–180. DOI: 10.1136/bjo.2005.077800.
Beckers HJ, Kinders KC, et al. Five-year results of trabeculectomy with mitomycin C. Graefes Arch Clin Exp Ophthalmol 2003;241(2):106.110. DOI: 10.1007/s00417-002-0621-5.
Bindlish R, Condon GP, et al. Efficacy and safety of mitomycin-C in primary trabeculectomy: five-year follow-up. Ophthalmology 2002;109(7):1336.1341. DOI: 10.1016/S0161-6420(02)01069-2, discussion 1341.1332.
Li Z, Van Bergen T, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2009;50(11):5217.5225. DOI: 10.1167/iovs.08-2662.
Goldberg AD, Allis CD, et al. Epigenetics: a landscape takes shape. Cell 2007;128(4):635.638. DOI: 10.1016/j.cell.2007.02.006.
Kouzarides T. Chromatin modifications and their function. Cell 2007;128(4):693.705. DOI: 10.1016/j.cell.2007.02.005.
Heerboth S, Lapinska K, et al. Use of epigenetic drugs in disease: an overview. Genet Epigenet 2014;6:9.19. DOI: 10.4137/GEG.S12270.
He S, Li X, et al. Review: epigenetic mechanisms in ocular disease. Mol Vis 2013;19:665.674.
Biermann J, Grieshaber P, et al. Valproic acid-mediated neuroprotection and regeneration in injured retinal ganglion cells. Invest Ophthalmol Vis Sci 2010;51(1):526.534. DOI: 10.1167/iovs.09-3903.
Gauthier AC, Liu J. Epigenetics and Signaling Pathways in Glaucoma. Biomed Res Int 2017;2017:5712341. DOI: 10.1155/2017/5712341.
Kavanaugh SM, White LA, et al. Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 2010;67(10):793.797. DOI: 10.2146/ajhp090247.
Sanders YY, Hagood JS, et al. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice. Eur Respir J 2014;43(5):1448.1458. DOI: 10.1183/09031936.00095113.
Sharma A, Sinha NR, et al. Role of 5′ŒTG3′Œ-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition. Mol Vis 2015;21:974.984.
Komorowsky C, Ocker M, et al. Differential regulation of connective tissue growth factor in renal cells by histone deacetylase inhibitors. J Cell Mol Med 2009;13(8B):2353.2364. DOI: 10.1111/j.1582- 4934.2008.00674.x.
Tandon A, Tovey JC, et al. Vorinostat: a potent agent to prevent and treat laser-induced corneal haze. J Refract Surg 2012;28(4):285.290. DOI: 10.3928/1081597X-20120210-01.
Li X, Zhou Q, et al. Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model. Mol Pharm 2013;10(1):307.318. DOI: 10.1021/mp300445a.
Min J, Lukowski ZL, et al. Comparison of single vs multiple injections of the protein saratin for prolonging bleb survival in a rabbit model. Invest Ophthalmol Vis Sci 2012;53(12):7625.7630. DOI: 10.1167/iovs. 12-10120.
Min J, Lukowski ZL, et al. Prevention of ocular scarring post glaucoma filtration surgery using the inflammatory cell and platelet binding modulator saratin in a rabbit model. PLoS One 2012;7(4):e35627. DOI: 10.1371/journal.pone.0035627.
Rodgers CD, Meyer AM, et al. The impact of conjunctival flap method and drainage cannula diameter on bleb survival in the rabbit model. PLoS One 2018;13(5):e0196968. DOI: 10.1371/journal.pone.0196968.
Fuchshofer R, Tamm ER. The role of TGF-beta in the pathogenesis of primary open-angle glaucoma. Cell Tissue Res 2012;347(1):279.290. DOI: 10.1007/s00441-011-1274-7.
Bermudez JY, Webber HC, et al. HDAC Inhibitor-Mediated Epigenetic Regulation of Glaucoma-Associated TGFbeta2 in the Trabecular Meshwork. Invest Ophthalmol Vis Sci 2016;57(8):3698.3707. DOI: 10.1167/iovs16-19446.
Sharma A, Mehan MM, et al. Trichostatin a inhibits corneal haze in vitro and in vivo. Invest Ophthalmol Vis Sci 2009;50(6):2695.2701. DOI: 10.1167/iovs.08-2919.
Kim TH, Kim SW, et al. Co-treatment of suberoylanilide hydroxamic acid and mitomycin-C induces the apoptosis of rabbit tenon's capsule fibroblast and improves the outcome of glaucoma filtration surgery. Curr Eye Res 2008;33(3):237.245. DOI: 10.1080/02713680701875281.
Doyle JW, Sherwood MB, et al. Intraoperative 5-fluorouracil for filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 1993;34(12):3313.3319.
Wong TT, Mead AL, et al. Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2003;44(3):1097.1103. DOI: 10.1167/iovs.02-0366.
Cordeiro MF, Mead A, et al. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther 2003;10(1):59.71. DOI: 10.1038/sj.gt.3301865.
Sharma A, Anumanthan G, et al. Epigenetic Modification Prevents Excessive Wound Healing and Scar Formation After Glaucoma Filtration Surgery. Invest Ophthalmol Vis Sci 2016;57(7):3381.3389. DOI: 10.1167/iovs.15-18750.